Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
ST

NASDAQ · STAA

STAAR Surgical Company

Healthcare · Medical - Instruments & Supplies

$23.42

Down-$0.20 (-0.85%)

Updated Sep 11, 2026, 6:03 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.22B
P/E ratio
-12.83
Dividend yield
0.00%
52-week range
$15.59 – $35.87
Volume
680.98K
Avg. volume
1.06M

Price performance

STAA price history

1M range · 20 trading sessions · Daily adjusted prices

STAA closed at $23.42 after 20 trading sessions, down 7.54% for the selected period.

Last close
$23.42
Period change
-7.54%
Period low
$22.11
Period high
$26.18
Daily close
View OHLC price history
STAA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$23.36$23.741$23.02$23.42680.98K
Sep 9, 2026$23.90$24.265$23.37$23.62827.85K
Sep 8, 2026$23.14$24.355$22.66$24.161.4M
Sep 4, 2026$23.47$24.365$23.40$23.471.97M
Sep 3, 2026$23.15$23.68$22.71$23.575798.35K
Sep 2, 2026$23.41$23.845$23.04$23.11472.78K
Sep 1, 2026$22.59$23.59$22.3583$23.52737.82K
Aug 31, 2026$22.07$22.94$21.77$22.59787.34K
Aug 28, 2026$22.33$22.45$21.89$22.11442.99K
Aug 27, 2026$22.67$22.8211$22.31$22.39565.3K
Aug 26, 2026$22.91$23.165$22.57$22.86427.93K
Aug 25, 2026$23.21$23.46$22.82$23.18523.01K
Aug 24, 2026$23.16$23.56$22.885$23.26562.08K
Aug 21, 2026$23.04$23.46$23.04$23.14698.5K
Aug 20, 2026$24.49$24.75$22.9766$23.07813.28K
Aug 19, 2026$24.77$25.56$24.39$24.661.02M
Aug 18, 2026$24.07$25.025$23.75$24.64928.45K
Aug 17, 2026$25.96$25.96$23.82$24.091.54M
Aug 14, 2026$25.15$26.245$24.81$26.18993.76K
Aug 13, 2026$24.08$25.58$23.25$25.331.86M

Latest STAA news

The latest Smart Investors Daily articles mentioning STAA.

Stock researchCompany · Overview

STAA research

Overview

Company profile and research snapshot.

Company profile

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.83
Implied upside
—
Analysts
—
STAA recent ratings
DateFirmRatingTarget
Aug 17, 2026StifelHold—
Aug 13, 2026UBSSell—
Aug 13, 2026WedbushOutperform—
Aug 4, 2026WedbushOutperform—
Jul 28, 2026UBSSell—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

LAKE FOREST, Calif., September 08, 2026--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer.

Yahoo · Sep 3, 2026

1 Russell 2000 Stock for Long-Term Investors and 2 Facing Challenges

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Yahoo · Sep 2, 2026

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif., September 02, 2026--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer.

Yahoo · Aug 27, 2026

1 Cash-Burning Stock to Keep an Eye On and 2 We Turn Down

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By